Literature DB >> 23658457

Gender, cytidine deaminase, and 5-aza/decitabine--response.

Reda Z Mahfouz, Lip Seng Koh, Marissa Teo, Chit Lai Chee, Han Chong Toh, Yogen Saunthararajah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23658457      PMCID： PMC4122236          DOI： 10.1158/1078-0432.CCR-13-0872

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Purification and properties of cytidine deaminase from normal and leukemic granulocytes.

Authors:  B A Chabner; D G Johns; C N Coleman; J C Drake; W H Evans
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

2.  Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.

Authors:  C Tibaldi; E Giovannetti; M Tiseo; L G Leon; A D'Incecco; N Loosekoot; M Bartolotti; R Honeywell; F Cappuzzo; A Ardizzoni; G J Peters
Journal:  Ann Oncol       Date:  2011-06-07       Impact factor: 32.976

Review 3.  Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.

Authors:  Steven D Gore; Evelyn R Hermes-DeSantis
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

4.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

5.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113
  5 in total
  4 in total

Review 1.  Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.

Authors:  Hetty E Carraway
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Authors:  Eric Laille; Tao Shi; Guillermo Garcia-Manero; Christopher R Cogle; Steven D Gore; Joel Hetzer; Keshava Kumar; Barry Skikne; Kyle J MacBeth
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 3.  Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Authors:  Andrea Kuendgen; Catharina Müller-Thomas; Michael Lauseker; Torsten Haferlach; Petra Urbaniak; Thomas Schroeder; Carolin Brings; Michael Wulfert; Manja Meggendorfer; Barbara Hildebrandt; Beate Betz; Brigitte Royer-Pokora; Norbert Gattermann; Rainer Haas; Ulrich Germing; Katharina S Götze
Journal:  Oncotarget       Date:  2018-06-12

4.  Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.

Authors:  Xiaorong Gu; Rita Tohme; Benjamin Tomlinson; Nneha Sakre; Metis Hasipek; Lisa Durkin; Caroline Schuerger; Dale Grabowski; Asmaa M Zidan; Tomas Radivoyevitch; Changjin Hong; Hetty Carraway; Betty Hamilton; Ronald Sobecks; Bhumika Patel; Babal K Jha; Eric D Hsi; Jaroslaw Maciejewski; Yogen Saunthararajah
Journal:  Leukemia       Date:  2020-08-07       Impact factor: 12.883
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.